Varex Imaging Corp VREX revenue by segment, product and geography
In its fiscal year ending 2025-09-30, Varex Imaging Corp reported revenue across 2 business segments; the largest, Medical Segment, was $593M, 70.2% of the filed sum (+1.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Medical Segment$593M70.2%+1.9% yoy
- Industrial Segment$252M29.8%+9.9% yoy
Members sum to the consolidated $845M for this period.
- Other countries$318Mshare n/a+0.2% yoy
- EMEA$285Mshare n/a+1.6% yoy
- Asia Pacific$283Mshare n/a+7.2% yoy
- Americas$277Mshare n/a+3.8% yoy
- United States$255Mshare n/a-1.1% yoy
- Japan$144Mshare n/a+21.5% yoy
- China$128Mshare n/a+8.7% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Medical Segment$156M72.3%+1.6% yoy
- Industrial Segment$59.8M27.7%+1.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.